Drugs Made in America AcquisDMAAU
13F holders, Q3 2025 (September 30)8holders −1
1new positions
2sold out
1famous investor
$10.20avg. 13F price*
At the end of Q3 2025, 8 institutions reported holding Drugs Made in America Acquis (DMAAU) in their 13F filings, down 1 from Q2 2025. 1 opened new positions and 2 sold out. The largest holders were KRYGER CAPITAL Ltd ($3.0M), Wolverine Asset Management LLC ($1.4M) and Rivernorth Capital Management, LLC ($1.1M). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Drugs Made in America Acquis
- CUSIP
- G2847J120
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3.0M |
| Exits | 2 | $3.2M |
All 13F filers, Q2 2025 → Q3 2025: 300,000 shares bought and 627,488 shares sold, net −327,488 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| KRYGER CAPITAL Ltd | 0.34% | New | 300,000 | $3.0M |
| Wolverine Asset Management LLC | 0.09% | No change | 130,000 | $1.4M |
| Rivernorth Capital Management, LLC | 0.06% | Reduce -75.7% | 102,372 | $1.1M |
| Clear Street Group Inc. | 0.00% | — | 47,483 | $494K |
| Robinson Capital Management, LLC | 0.23% | No change | 30,000 | $314K |
| Tuttle Capital Management, LLC | 0.79% | No change | 20,000 | $208K |
| UBS Group AG | 0.00% | No change | 18,385 | $191K |
| Citadel Advisors | 0.00% | Reduce -14.7% | 11,964 | $125K |
"% of holder's portfolio" is DMAAU's weight in each manager's 13F, not the share of Drugs Made in America Acquis the manager owns.